Emily Leproust
Investment Committee @ NFX Bio
San Francisco, United States
Emily Leproust is a seed investor at NFX Bio in San Francisco focused on Biotechnology and Health Care. As an early pioneer in long DNA synthesis, Emily is poised to accelerate the biofactory market. She and co-founder Bill Peck share the world record for synthesizing the longest, highest quality oligo library. Emily architected the successful SureSelect product line which lowered the cost of sequencing and elucidated dozens of mendelian diseases,and she developed Agilent’s Oligo Library Synthesis technology. Emily has co-authored over 34 peer-reviewed papers—many on synthetic DNA—and has extensive marketing, management, and business development experience. Prior to Twist Bioscience, Emily was Director of Applications and Chemistry R&D—Genomics at Agilent Technologies.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Emily Leproust invests in
Stages Emily Leproust invests in
Countries Emily Leproust invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.5M–$5.7M
Investment Focus
Industry
- Biotechnology 3 (100%)
- Health Care 2 (67%)
- Product Research 1 (33%)
- Food and Beverage 1 (33%)
Country
- United States 2 (67%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biostate AI
|
Biostate AI develops generative AI that benefit all human health. | $4M / Seed / Jul 08, 2024 | |
Cradle
|
Using robust prediction algorithms and AI design recommendations, Cradle assists biologists in rapidly designing better proteins. Cradle gives you complete ownership of the intellectual property while maintaining the privacy and security of your sequences and data. | $5.7M / Seed / Nov 16, 2022 | |
Kiwi Biosciences
|
Kiwi biosciences is a biotech company that develops enzymes to make food for patients who suffer from Irritable Bowel Syndrome (IBS). The company was founded in 2020 and is based in Somerville, Massachusetts, United States. | $1.5M / Seed / Oct 14, 2021 |
Co-Investors
About NFX Bio
NFX Bio is a fund initiative that seeks to invest in scientist-founders at the seed stage with a technology platform approach.Led by Omri Amirav Drory, a venture partner with NFX, who founded Genome Compiler, it helps scientists learn to be founders and guides biology companies with information technology to be a critical distinction with massiveimplications.
NFX Bio Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Emily Leproust
Investment Committee
|
|||
Gigi Levy Weiss
Investment Committee
|
|||
Gita Reinitz
Principal
|
|||
James Currier
Investment Committee
|
|||
Omri Amirav-Drory
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Emily Leproust invest in?
Emily Leproust invests primarily in Biotechnology, Health Care and Product Research startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Emily Leproust's check size?
Emily Leproust typically joins rounds of $1.5M–$5.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Emily Leproust participates in.
How do I contact Emily Leproust?
Public channels for Emily Leproust include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Emily Leproust last invest?
The most recent investment recorded for Emily Leproust closed in Jul 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
